Next-generation screen for integrative subtyping and target discovery for KRAS-mutant cancer

被引：0

作者：

Yuan, Tina L. ^{[1
]}

Bagni, Rachel ^{[2
]}

Yi, Ming ^{[2
]}

Amzallag, Arnaud ^{[3
,4
]}

Afghani, Shervin ^{[1
]}

Beam, Katie ^{[2
]}

Burgan, William ^{[2
]}

Fer, Nicole ^{[2
]}

Garvey, Leslie ^{[2
]}

Smith, Brian ^{[2
]}

Waters, Andrew ^{[2
]}

Stephens, Robert ^{[2
]}

Benes, Cyril ^{[3
,4
]}

McCormick, Frank ^{[1
]}

机构：

[1] UCSF Helen Diller Comprehens Canc Ctr, San Francisco, CA USA

[2] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Canc Res Technol Program, Frederick, MD USA

[3] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA USA

[4] Harvard Univ, Sch Med, Boston, MA USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.AM2015-4690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4690

引用

页数：2

共 50 条

[21] Next-generation genomics: an integrative approach
Hawkins, R. David
Hon, Gary C.
Ren, Bing
[J]. NATURE REVIEWS GENETICS, 2010, 11 (07) : 476 - 486
[22] Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer
Cox, Adrienne D.
Goodwin, Craig M.
Bryant, Kirsten L.
Dagliyan, Irem
George, Samuel D.
Lucas, Kelly E.
Gautam, Prson
Wennerberg, Krister
Der, Channing J.
[J]. CANCER RESEARCH, 2018, 78 (13)
[23] Endoplasmic Reticulum: Target for Next-Generation Cancer Therapy
Banerjee, Samya
Zhang, Wenying
[J]. CHEMBIOCHEM, 2018, 19 (22) : 2341 - 2343
[24] The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer
Goldberg, Sarah B.
Herbst, Roy S.
[J]. LANCET, 2023, 401 (10378): : 706 - 707
[25] Chromatin condensation in KRAS-mutant lung cancer as a therapeutic target: challenging the paradigm of associating KRAS mutation with EGFR inhibitor resistance
Wang, Meng
Kern, Ashley M.
Huelskoetter, Marieke
Greninger, Patricia
Singh, Anurag
Pan, Yunfeng
Chowdhury, Dipanjan
Krause, Mechthild
Baumann, Michael
Benes, Cyril H.
Efstathiou, Jason A.
Settleman, Jeff
Willers, Henning
[J]. CANCER RESEARCH, 2014, 74 (19)
[26] MET inhibition radiosensitizes KRAS-mutant rectal cancer.
D'Ambrosio, Antonio
Verginelli, Federica
Orzan, Francesca
Albano, Raffaella
Casanova, Elena
Luraghi, Paolo
De Bacco, Francesca
Bertotti, Andrea
Trusolino, Livio
Senetta, Rebecca
Sapino, Anna
Del Mastro, Elena
Gatti, Marco
Comoglio, Paolo M.
Boccaccio, Carla
[J]. CANCER RESEARCH, 2021, 81 (13)
[27] Dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab
Lisa Hutchinson
[J]. Nature Reviews Clinical Oncology, 2011, 8 (4) : 193 - 193
[28] A novel combination strategy to treat KRAS-mutant lung cancer
Peng, R. -W.
Liang, S. -Q.
Buhrer, E. D.
Berezowska, S.
Marti, T. M.
Froment, L.
Yang, H.
Hall, S. R.
Vassella, E.
Yang, Z.
Kocher, G. J.
Amrein, M. J.
Riether, C.
Ochsenbein, A. F.
Schmid, R. A.
[J]. BRITISH JOURNAL OF SURGERY, 2019, 106 : 19 - 19
[29] Immunogenic chemotherapy effectively constrains KRAS-mutant lung cancer
Wang, D.
Cong, J.
Fu, B.
Zheng, X.
Sun, R.
Tian, Z.
Wei, H.
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1893 - 1893
[30] Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Blake, Devon R.
Vaseva, Angelina V.
Hodge, Richard G.
Kline, McKenzie P.
Gilbert, Thomas S. K.
Tyagi, Vikas
Huang, Daowei
Whiten, Gabrielle C.
Larson, Jacob E.
Wang, Xiaodong
Pearce, Kenneth H.
Herring, Laura E.
Graves, Lee M.
Frye, Stephen V.
Emanuele, Michael J.
Cox, Adrienne D.
Der, Channing J.
[J]. SCIENCE SIGNALING, 2019, 12 (590)

← 1 2 3 4 5 →